Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Richard Bourgon"'
Autor:
Radia M. Johnson, Xueping Qu, Chu-Fang Lin, Ling-Yuh Huw, Avinashnarayan Venkatanarayan, Ethan Sokol, Fang-Shu Ou, Nnamdi Ihuegbu, Oliver A. Zill, Omar Kabbarah, Lisa Wang, Richard Bourgon, Felipe de Sousa e Melo, Chris Bolen, Anneleen Daemen, Alan P. Venook, Federico Innocenti, Heinz-Josef Lenz, Carlos Bais
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated colorectal cancer tumors, however, its relationship with treatment response remains to be explored. Here, the authors suggest that ARID1A mutations may confer intrinsic
Externí odkaz:
https://doaj.org/article/4488b89ca7bf43bdb1d09041a86d2a0c
Autor:
Mélanie Desbois, Akshata R. Udyavar, Lisa Ryner, Cleopatra Kozlowski, Yinghui Guan, Milena Dürrbaum, Shan Lu, Jean-Philippe Fortin, Hartmut Koeppen, James Ziai, Ching-Wei Chang, Shilpa Keerthivasan, Marie Plante, Richard Bourgon, Carlos Bais, Priti Hegde, Anneleen Daemen, Shannon Turley, Yulei Wang
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
The exclusion of T cells from solid tumours is a potentially important mechanism that regulates whether or not cancer patients respond well to checkpoint blocking immunotherapies. Here the authors identify immune phenotypes and mediators of T cell ex
Externí odkaz:
https://doaj.org/article/e31d51185c324442b45c5107128325ef
Autor:
Yu Kong, Christopher M. Rose, Ashley A. Cass, Alexander G. Williams, Martine Darwish, Steve Lianoglou, Peter M. Haverty, Ann-Jay Tong, Craig Blanchette, Matthew L. Albert, Ira Mellman, Richard Bourgon, John Greally, Suchit Jhunjhunwala, Haiyin Chen-Harris
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
Treatment with demethylation agents can reactivate transposable elements. Here in glioblastoma, the authors also show that this is accompanied by de novo presentation of TE-derived peptides on MHC class I molecules.
Externí odkaz:
https://doaj.org/article/4f372d927b9744d19d8bbddc89834da4
Autor:
Andrew Wallace, Ryan Jones, Richard Bourgon, Guang-Yu Yang, Amy A Lo, Daniel Oreper, Nicolas Lounsbury, Charles Havnar, Ximo Pechuan-Jorge, Thomas D Wu, Katrina Krogh, Oliver A Zill
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/ae3220fd2a674ad6a63ade71ac6c61d6
Autor:
Anneleen Daemen, Akshata R. Udyavar, Thomas Sandmann, Congfen Li, Linda J. W. Bosch, William O’Gorman, Yijin Li, Amelia Au-Yeung, Chikara Takahashi, Omar Kabbarah, Richard Bourgon, Priti Hegde, Carlos Bais, Meghna Das Thakur
Publikováno v:
PLoS ONE, Vol 16, Iss 12 (2021)
Background Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with a 5% 5-year survival rate for metastatic disease, yet with limited therapeutic advancements due to insufficient understanding of and inability to accurately capture
Externí odkaz:
https://doaj.org/article/ceb3d9ff0113422f8fd18c42ca9291dd
Autor:
Yasin Senbabaoglu, Aslihan Calviello, Guadalupe Munoz, Richard Bourgon, Shannon Turley, Christine Moussion
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/0f7035c4bac14dc6b529f219e70c6aa5
Autor:
Christopher R. Bolen, Ronald McCord, Sarah Huet, Garrett M. Frampton, Richard Bourgon, Fabrice Jardin, Peggy Dartigues, Elizabeth A. Punnoose, Edith Szafer-Glusman, Luc Xerri, Pierre Sujobert, Gilles Salles, Jeffrey M. Venstrom
Publikováno v:
Blood Advances, Vol 1, Iss 22, Pp 1884-1890 (2017)
Abstract: Identifying follicular lymphoma (FL) patients with preexisting antitumor immunity will inform precision medicine strategies for novel cancer immunotherapies. Using clinical and genomic data from 249 FL patients, we determined the clinical i
Externí odkaz:
https://doaj.org/article/077c0f2c08d74e3c89a954500baaa162
Autor:
Nisebita Sahu, Jean-Philippe Stephan, Darlene Dela Cruz, Mark Merchant, Benjamin Haley, Richard Bourgon, Marie Classon, Jeff Settleman
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
Acquired resistance significantly limits the efficacy of cancer drug therapies. Here, the authors identify miR-371-3p as a suppressor of drug tolerance in cancer cell lines by its target gene PRDX6, which in turn regulates PLA2/PKCα signalling and R
Externí odkaz:
https://doaj.org/article/01cff8d056c9437f9bb6381d87492a43
Autor:
May M Y Liang-Chu, Mamie Yu, Peter M Haverty, Julie Koeman, Janet Ziegle, Marie Lee, Richard Bourgon, Richard M Neve
Publikováno v:
PLoS ONE, Vol 10, Iss 2, p e0116218 (2015)
Cell lines are the foundation for much of the fundamental research into the mechanisms underlying normal biologic processes and disease mechanisms. It is estimated that 15%-35% of human cell lines are misidentified or contaminated, resulting in a hug
Externí odkaz:
https://doaj.org/article/1c54e13500854a95bac5ed8bedd7df83
Autor:
Yuri B Schwartz, Tatyana G Kahn, Per Stenberg, Katsuhito Ohno, Richard Bourgon, Vincenzo Pirrotta
Publikováno v:
PLoS Genetics, Vol 6, Iss 1, p e1000805 (2010)
Polycomb (PcG) regulation has been thought to produce stable long-term gene silencing. Genomic analyses in Drosophila and mammals, however, have shown that it targets many genes, which can switch state during development. Genetic evidence indicates t
Externí odkaz:
https://doaj.org/article/4f8d22b8028d49d69d1c2048091b9280